Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Pharmaceuticals Inc. has initiated PRESERVE, a Phase 4 study to evaluate the combination of LUPKYNIS with belimumab, obinutuzumab, or anifrolumab in approximately 150 lupus nephritis patients across 50 U.S. sites. The study aims to improve complete renal response rates, as LUPKYNIS is currently the only FDA-approved oral therapy for lupus nephritis shown to significantly increase CRR at 6 months. Researchers believe a multi-target therapeutic approach could accelerate nephron damage cessation and preserve kidney function.
Aurinia Unchanged on Unveiling Lupus Treatment
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the initiation of PRESERVE, a Phase 4 study combining LUPKYNIS® with other treatments for lupus nephritis. The study aims to enroll 150 patients across 50 U.S. sites, with the primary endpoint being complete renal response at six months. LUPKYNIS is currently the only FDA-approved oral therapy for lupus nephritis that has demonstrated a statistically significant increase in complete renal response.
Aurinia Unchanged on Unveiling Lupus Treatment
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) remained flat in early Monday trading following its announcement of the initiation of PRESERVE, a Phase 4 study for lupus nephritis. This study will investigate the combination of LUPKYNIS® with other treatments like belimumab, obinutuzumab, or anifrolumab in approximately 150 patients. The primary goal is to assess the proportion of patients achieving complete renal response at six months, with experts emphasizing the importance of rapidly arresting proteinuria for kidney damage prevention.
Aurinia launches trial combining lupus nephritis treatments
Aurinia Pharmaceuticals has initiated a Phase 4 study called PRESERVE to investigate combining LUPKYNIS with other approved lupus nephritis treatments. The trial aims to enroll 150 patients across 50 U.S. sites, focusing on achieving complete renal response at 6 months. Aurinia also recently completed the acquisition of Kezar Life Sciences, further expanding its biopharmaceutical capabilities.
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Pharmaceuticals Inc. has announced the initiation of PRESERVE, a Phase 4 study investigating the combination of its drug LUPKYNIS with belimumab, obinutuzumab, or anifrolumab in patients with lupus nephritis. With a planned enrollment of 150 patients across 50 U.S. sites, the study's primary goal is to determine the proportion of patients achieving complete renal response at 6 months. This research aims to explore a multitarget therapeutic approach, leveraging the different mechanisms of action of these agents to improve treatment outcomes for lupus nephritis.
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Pharmaceuticals has initiated the PRESERVE study, a Phase 4 multicenter trial investigating LUPKYNIS in combination with belimumab, obinutuzumab, or anifrolumab for lupus nephritis patients. The study aims to achieve complete renal response at 6 months by employing a multitarget therapeutic approach. Industry experts believe combining LUPKYNIS, the only FDA-approved oral therapy for lupus nephritis, with these biologic agents could significantly improve patient outcomes by intervening in different biological pathways contributing to kidney damage.
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Pharmaceuticals Inc. has initiated the PRESERVE study, a Phase 4 multicenter trial to investigate the combination of LUPKYNIS with belimumab, obinutuzumab, or anifrolumab in approximately 150 lupus nephritis patients across 50 U.S. sites. The primary endpoint is the proportion of patients achieving complete renal response at 6 months. This study aims to explore a multi-target therapeutic approach to improve outcomes in lupus nephritis, as LUPKYNIS is currently the only FDA-approved oral therapy for this condition.
Enterprise value to EBITDA forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH
This article provides a financial overview of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), specifically focusing on its enterprise value to EBITDA forward metric. It details the stock's market information, financial data availability, and resources for further analysis on TradingView.
If You Invested $1,000 in Aurinia Pharmace (AUPH)
This article examines the historical performance of investing $1,000 in Aurinia Pharmaceuticals (AUPH) over various periods, showing significant returns, particularly for investments made one and ten years ago. It also provides an overview of Aurinia Pharma, highlighting its commercial product LUPKYNIS for lupus nephritis and its pipeline product aritinercept (AUR200) for autoimmune diseases. The company's financial reporting, regulatory considerations, and engagement in medical conferences are also discussed, alongside a comparison of AUPH's performance against the S&P 500.
Aurinia Announces Management Transition
Aurinia Pharmaceuticals Inc. announced a management transition where Kevin Tang, the Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter Greenleaf will stay on as a consultant to assist with the handover. The company also appointed Ryan Cole as COO, Michael Hearne as CFO, and Thomas Wei as CSO, while Stew Kroll and Stephen Robertson will continue in their current roles.
If EPS Growth Is Important To You, Aurinia Pharmaceuticals (NASDAQ:AUPH) Presents An Opportunity
This article analyzes Aurinia Pharmaceuticals' recent earnings per share (EPS) growth, noting a significant improvement over the past year. While past performance doesn't guarantee future results, the company's positive trajectory could indicate a promising investment opportunity for those prioritizing EPS growth. The analysis suggests that Aurinia has effectively converted its revenue into profit growth.
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
Aurinia Pharmaceuticals (AUPH) has been upgraded to a Zacks Rank #1 (Strong Buy) due to a positive shift in its earnings outlook, which is considered a powerful driver of stock prices. The upgrade reflects rising earnings estimates for the biotech company, with an expected earning of $0.86 per share for fiscal year 2026, and a 0.6% increase in the Zacks Consensus Estimate over the past three months. This places AUPH in the top 5% of Zacks-covered stocks for estimate revisions, suggesting potential for market-beating returns.
AUPH - Aurinia Pharmaceuticals Inc Latest SEC Filings
This article provides a detailed financial overview of Aurinia Pharmaceuticals Inc (AUPH), including its latest stock performance, market capitalization, income statement details, and key financial ratios. It also lists insider and institutional ownership, analyst recommendations, and various performance metrics over different periods. The data indicates a recent stock price decline but strong long-term performance and profitability.
Why (AUPH) Price Action Is Critical for Tactical Trading
This article analyzes Aurinia Pharmaceuticals Inc (AUPH) stock, highlighting a weak near-term sentiment but strong mid and long-term outlook. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for different risk profiles. The analysis emphasizes the importance of AUPH's price action for tactical trading, noting exceptional risk-reward short setup potential.
AUPH - Aurinia Pharmaceuticals Inc Options
This article provides a comprehensive overview of Aurinia Pharmaceuticals Inc. (AUPH) stock options and detailed financial data. It includes key metrics such as market capitalization, income, sales, P/E ratio, EPS, insider and institutional ownership, and various performance indicators. The data highlights the company's financial health, stock performance, and analyst recommendations.
IKAP Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Aurinia Pharmaceuticals Inc. (IKAP) stock, based on analyst opinions. It includes financial data such as historical stock prices, earnings, revenue, and EBITDA, along with information on future earnings reports and dividend policy.
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Aurinia Pharmaceuticals Inc (AUPH), detailing its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. While technical indicators show mixed signals, moving averages predominantly suggest a "Buy" signal. The analysis aims to offer investors reference points for potential trading decisions.
Enterprise value to EBIT forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH
This article provides financial information for Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), specifically its Enterprise Value to EBIT (Earnings Before Interest and Taxes) forward metric. It also lists general market data, tools, and community links associated with TradingView, where this financial snapshot is presented.
Price to sales forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH
This article provides the "Price to sales forward" metric for Aurinia Pharmaceuticals Inc (NASDAQ: AUPH). It is a financial data point for the biotechnology company, indicating a valuation ratio that compares a company's stock price to its revenue per share. The specific value and change percentage for this metric are presented for a defined period.
Aurinia Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:AUPH)
This article provides an overview of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) financials and analyst estimates. It includes current stock price, historical performance, analyst price targets, upcoming earnings dates, and details on past earnings and revenue. The company's market capitalization, EBITDA, and employee count are also noted.
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
The drug and biotech sector is showing strong signs of recovery after a challenging period, driven by robust quarterly results, increased M&A activity, and pipeline successes. Innovation in areas like obesity treatments, next-gen oncology, and gene editing, along with the application of AI in drug discovery, are key growth drivers. Amid this optimistic outlook, Zacks Equity Research highlights five small drug stocks—Indivior Pharmaceuticals, Aurinia Pharmaceuticals, Ironwood Pharmaceuticals, Altimmune, and Marker Therapeutics—as promising investment opportunities.
Aurinia Pharmaceuticals Inc. Actuals & Estimates (SWB:IKAP)
This article provides an overview of Aurinia Pharmaceuticals Inc. (SWB:IKAP) financials, analyst estimates, and key historical data. It includes information on future price targets, past earnings performance, revenue figures, current EBITDA, and the company's employee count. The article also addresses common investor questions about the stock, including how to buy shares and upcoming earnings dates.
IKAP Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Aurinia Pharmaceuticals Inc. (IKAP) stock, based on analyst opinions. It includes details on the company's past performance, earnings, revenue, and other financial metrics, noting that despite estimates, IKAP does not pay dividends.
Price to earnings forward of Aurinia Pharmaceuticals Inc. – LSX:A1W7D4
The article focuses on the "Price to earnings forward" metric for Aurinia Pharmaceuticals Inc. (LSX:A1W7D4), available on TradingView. It provides a snapshot of this specific financial data point for the company within the health technology and biotechnology sector on the Lang & Schwarz Exchange. The article is primarily a data presentation with no additional analytical content.
AUPH Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Aurinia Pharmaceuticals Inc (AUPH) stock for 2027, based on analyst opinions. It includes current stock performance, historical highs and lows, market capitalization, volatility, and upcoming earnings information. The report also highlights financial data such as recent EPS and revenue figures, and analyst ratings for AUPH.
Enterprise value to revenue forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH
This article provides financial information for Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), specifically focusing on its enterprise value to revenue forward metric. The content highlights the company's financial data as presented on TradingView.
Price to sales forward of Aurinia Pharmaceuticals Inc. – LSX:A1W7D4
This article focuses on the "Price to sales forward" metric for Aurinia Pharmaceuticals Inc. (LSX:A1W7D4) as listed on the Lang & Schwarz Exchange. It appears to be a financial data point or a section within a larger financial overview on the TradingView platform. The content primarily highlights the company's financial data access through various market data providers.
Aurinia Pharmaceuticals stock hits 52-week high at 17.44 USD
Aurinia Pharmaceuticals stock reached a new 52-week high of $17.44, with shares currently trading at $17.54, suggesting potential further upside according to InvestingPro analysis. The company has seen a significant 1-year change of 110.22% and recently completed the acquisition of Kezar Life Sciences, Inc., further solidifying its market position. Kevin Tang has also been appointed as the new CEO.
Understanding Momentum Shifts in (AUPH)
This article analyzes Aurinia Pharmaceuticals Inc (AUPH), indicating a strong overweight bias across all time horizons due to strong sentiment. It identifies a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies with specific entry, target, and stop-loss points for different risk profiles. The analysis also highlights strong signal strength and support/resistance levels across near-term, mid-term, and long-term horizons for AUPH.
How New LUPKYNIS Renal Outcomes Data Could Impact Aurinia Pharmaceuticals (AUPH) Investors
Aurinia Pharmaceuticals recently announced new AURORA 1 Phase 3 analysis at the EULAR 2026 Congress, showing LUPKYNIS significantly reduced renal-related events or death in lupus nephritis patients. This data strengthens the clinical evidence for the drug but does not eliminate risks associated with reliance on a single product or future competition. Investors will be watching how this new information influences existing revenue guidance and long-term uptake.
Aurinia Pharmaceuticals Inc (AUPH) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Aurinia Pharmaceuticals Inc's (AUPH) shareholder structure, listing major shareholders and institutional holdings. It highlights top individual shareholders like Tang Capital Management, LLC and BlackRock, along with a classification of shareholder types. The article also presents institutional shareholding changes over several quarters and lists related ETF holdings.
Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Aurinia Pharmaceuticals Inc (AUPH), detailing regional contributions. It shows that the United States accounts for 93.21% of its revenue, totaling $263.84 million, while Japan contributes 6.79% with $19.21 million. Information on revenue by business segments and profit contribution has not yet been disclosed by the company.
Aurinia Pharmaceuticals Inc (AUPH) Earnings Forecast: Future EPS & Revenue Growth Estimates
Aurinia Pharmaceuticals Inc (AUPH) has an earnings forecast score of 7.43, ranking 291 out of 388 in its industry. Analysts have set an average price target of $17.00 for AUPH, with most supporting a "Buy" trend. The company's expected revenue for the next quarter is $79.70 million, and analysts anticipate EPS of $0.24 for the upcoming quarter.
Aurinia Pharmaceuticals and Four More Stocks See Activist Action
This article reports on recent activist actions disclosed to the SEC, specifically focusing on Aurinia Pharmaceuticals and four other companies. The information is derived from 13D filings, which are required when an entity acquires more than 5% ownership in a company's securities. The reported data covers filings made between June 4 and June 10, 2026.
Aurinia (NASDAQ: AUPH) director receives grant of 23,931 stock options
Aurinia Pharmaceuticals Inc. director Craig A. Johnson was granted 23,931 stock options as part of his compensation, with an exercise price of $15.67 per share. These options are set to vest one year from the grant date and will expire on June 4, 2036. The Form 4 filing indicates this was a grant, award, or other acquisition of derivative securities, and no open-market buying or selling was reported.
Aurinia (NASDAQ: AUPH) director awarded 23,931 stock options expiring 2036
Aurinia Pharmaceuticals director Kathleen Goetz was granted 23,931 Director Stock Options on June 4, 2026, as compensation. These options have an exercise price of $15.67 per share and will expire on June 4, 2036, vesting one year from the grant date. Following this award, her direct derivative holdings total 23,931 options.
Aurinia Pharmaceuticals (AUPH) director receives 23,931 share option grant
Aurinia Pharmaceuticals Inc. (AUPH) director Tina Susan Nova was granted 23,931 stock options as compensation, which are exercisable at $15.67 per share and will vest one year from the grant date of June 4, 2026. The options are set to expire on June 4, 2036. This transaction is classified as a grant/award acquisition, not a market purchase or sale of common shares.
Aurinia (AUPH) director Jeffrey Bailey granted 23,931 stock options at $15.67
Aurinia Pharmaceuticals Inc. director Jeffrey Allen Bailey was granted 23,931 stock options with an exercise price of $15.67 per share. These options are part of his compensation, will vest one year from the grant date, and are set to expire on June 4, 2036. This transaction reflects a new award and not an open-market purchase or sale.
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
Aurinia Pharmaceuticals' (AUPH) CEO, Kevin Tang, indirectly purchased 814,606 common shares across several transactions between May 29, 2026, and June 2, 2026, totaling approximately $12.5 million. This significant acquisition, representing 6.66% of his total holdings, occurred just before positive news about the company's lead drug, Lupkynis, which showed a more than 50% reduction in the risk of kidney-related events or death in lupus nephritis patients. Lupkynis sales are increasing, and the company is already profitable, making this insider buy a potentially smart move for investors.
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
Aurinia Pharmaceuticals' CEO, Kevin Tang, indirectly purchased 814,606 common shares for approximately $12.5 million between May 29 and June 2, 2026, through affiliated entities. This significant investment occurred shortly before the company reported positive long-term phase 3 trial results for its drug, Lupkynis, which showed a substantial reduction in kidney-related events for lupus nephritis patients. The article suggests that with rising profits and strong trial data, this CEO purchase signals a positive outlook for investors.
Insider sales, option exercise at AUPH (NASDAQ: AUPH) reported
A recently filed Form 144 for Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) details proposed and recent transactions involving option exercises and sales of common stock. The filing indicates a planned sale of 9,593 shares connected to an option exercise dated June 5, 2026, and also reports two past sales by Gregory Keenan totaling 50,000 shares on June 2 and June 4, 2026. These transactions involve significant financial figures, with one sale by Keenan valued at over $54 million.
10 Health Care Stocks Whale Activity In Today's Session
This article identifies significant "whale activity" in the options market for ten healthcare stocks, including Aurinia Pharmaceuticals (AUPH), UnitedHealth Group (UNH), and Eli Lilly and Co (LLY). It details specific bullish or bearish options trades, their expiration dates, strike prices, and total trade values, offering insights for traders interested in tracking large-scale institutional movements. The article also explains key options terminology to help readers understand the presented data.
Tang group discloses 10% Aurinia (AUPH) stake plus $15 put options
Tang Capital Management and affiliated entities have amended their Schedule 13D filing, revealing a beneficial ownership of 10.0% in Aurinia Pharmaceuticals Inc., totaling 13,044,106 common shares as of June 3, 2026. The filing also discloses that the group holds put option contracts to potentially purchase an additional 1,000,000 common shares at a strike price of $15.00, expiring on January 15, 2027. Kevin Tang, CEO and board member of Aurinia, shares voting and dispositive power over these shares, indicating a significant investment for control and potential future exposure.
AUPH: 25,000-share option exercise filed; Keenan sold 25,000 on 06/02/2026
A Form 144 filing for Aurinia Pharmaceuticals Inc. (AUPH) indicates a 25,000-share option exercise with a proposed sale on June 4, 2026, settled by cash. The filing also notes a previous sale by Gregory Keenan of 25,000 shares on June 2, 2026, for $54,100,000. These transactions contribute to transparency regarding insider stock movements.
Strong shareholder support for Aurinia (NASDAQ: AUPH) board, auditor and say-on-pay
Aurinia Pharmaceuticals Inc. shareholders demonstrated strong support for the company's leadership and compensation plan at its 2026 annual general meeting. All five director nominees were elected with significant majorities, ranging from 86.50% to 96.59% of votes. Additionally, shareholders approved the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm and passed a non-binding advisory "say on pay" resolution for executive compensation with 93.10% support.
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow (NASDAQ:AUPH)
Aurinia Pharmaceuticals (AUPH) is poised for profitable growth, buoyed by strong financial results from Lupkynis and strategic pipeline expansion through the Kezar Life Sciences acquisition. The company reported impressive 1Q26 figures, including double-digit revenue and net income growth, and robust cash flow, reaffirming its full-year guidance. With increased investment from Tang Capital Management and a diversified autoimmune platform, Aurinia aims to capitalize on new therapeutic opportunities and maintain its strong valuation.
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
A new analysis of the AURORA 1 Phase 3 study for LUPKYNIS in lupus nephritis patients showed a statistically significant 53% reduction in the risk of renal-related event or death. The study, presented at EULAR 2026 Congress, highlights LUPKYNIS' favorable effect on clinically important outcomes, including an 81% reduction in the risk of death and a 55% reduction in treatment failure. Aurinia Pharmaceuticals Inc., the developer of LUPKYNIS, emphasizes its role as the only FDA-approved oral therapy to demonstrate significant improvement in complete renal response for this condition.
Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common Stock
A 10% shareholder of Aurinia Pharmaceuticals (AUPH.US) recently purchased 2,367,314 shares of common stock for a total of US$12.46 million. This transaction occurred at an average price of US$5.26 per share. Following this purchase, the shareholder now directly owns 20,449,602 shares in the company.
Aurinia Pharmaceuticals Insider Bought Shares Worth $12,455,227, According to a Recent SEC Filing
This article reports on a significant insider purchase of Aurinia Pharmaceuticals shares. An insider acquired shares valued at $12,455,227, as disclosed in a recent SEC filing. This transaction could indicate insider confidence in the company's future prospects.
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.
TANG CAPITAL MANAGEMENT, LLC has filed an early warning report concerning Aurinia Pharmaceuticals Inc. (AUPH). Quantisnow, a market data and news platform, provided this update, alerting its Plus members shortly after publication. The platform aggregates real-time information such as SEC filings, FDA approvals, and insider trades for retail investors.
